TABLE 1.

Demographic and clinical characteristics of the study subjects.

	Patients with AD	Patients with MCI	Control subjects	p-value
	(n = 62)	(n = 47)	(n = 49)
Age	71.81 ± 7.98	72.73 ± 7.75	69.50 ± 5.94	0.079
Medium (range)	73 (57, 89)	74 (53, 87)	71 (57, 81)
Sex (M/F)	27/35	18/29	17/32	0.634
VA	0.68 ± 0.25	0.75 ± 0.22	0.70 ± 0.14	0.275
IOP (mmHg)	14.24 ± 2.55	14.62 ± 2.57	14.26 ± 2.20	0.718
HBP	22	19	18	0.865
DM	8	8	8	0.812
MMSE score	19.92 ± 4.54	28.04 ± 1.90	28.67 ± 1.0	<0.001**
Medium (range)	20 (7, 24)	28 (23, 30)	29 (27, 30)
CDR global	1.339 ± 0.061	0.532 ± 0.018	0.031 ± 0.017	<0.001**
MTA	1.77 ± 0.231	1.34 ± 0.143	0.89 ± 0.200	0.071
Fazekas	0.88 ± 0.234	0.71 ± 0.137	0.56 ± 0.176	0.598
GCA	1.46 ± 0.144	1.14 ± 0.147	0.780 ± 0.147	0.108
PCA	1.08 ± 0.178	0.76 ± 0.137	0.44 ± 0.176	0.257

Data reported as mean and SD (standard deviation) with p values. AD, Alzheimer’s disease; MCI, mild cognitive impairment; M, male; F, female; VA, visual acuity; IOP, intraocular pressure; HBP, high blood pressure; DM, diabetes mellitus; MMSE, Mini–Mental State Examination; CDR, clinical dementia rating, the global score of CDR was used. The bold values indicate statistical significance. **p < 0.01.